Skip to main content

Cancer Responsiveness Monitoring based on Resistance mutations in CTCs

Objective

Today's treatment of metastatic breast cancer is guided by characterisation of the primary tumour while 90% of deaths due to breast cancer occur as a consequence of metastases. Given important differences in molecular characteristics between metastases and primary tumour tissue, characterization of metastatic tumours instead of the primary tumour may provide better treatment guidance for patients with metastatic disease. Metastatic tumours are however difficult to assess using currently available techniques. We propose to clinically validate molecular methods and develop a clinically validated system for characterization of circulating tumour cells, used as proxies for the metastatic tumour, to guide treatment decisions in women with metastatic breast cancer. Two unique methods will be combined, single cell molecular characterization and improved circulating tumour cell sampling and identification, provided by the participating SMEs. Together with leading academic scientists and one industrial partner, the consortium is ideally suited to evaluate the clinical utility of the proposed methods and to validate the methods in order to reach the final development stage before the product will be introduced to the market, which constitutes a significant commercial potential for the SME-partners in the project.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /natural sciences/biological sciences/genetics and heredity/mutation
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/breast cancer

Call for proposal

FP7-HEALTH-2013-INNOVATION-2
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

Navinci Diagnostics AB
Address
Chemistry Bmc - Box 599
751 24 Uppsala
Sweden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 843 403,20
Administrative Contact
Caroline Kampf (Dr.)

Participants (4)

CYTOTRACK APS
Denmark
EU contribution
€ 1 926 596
Address
Gammel Lundtoftevej 1D
2800 Lyngby
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Tom Hede Markussen (Dr.)
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 1 473 852,80
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Raymond Castelijns (Mr.)
PHILIPS ELECTRONICS NEDERLAND BV
Netherlands
EU contribution
€ 737 980
Address
High Tech Campus 52
5656 AG Eindhoven
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Patrick Keur (Mr.)
STOCKHOLMS UNIVERSITET
Sweden
EU contribution
€ 145 800
Address
Universitetsvagen 10
10691 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ann Nielsen (Ms.)